Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
Commercial Sponsor
AstraZeneca
Summary
Eligible participants will be randomly allocated to either the Experimental or Placebo Comparator Arm. In the Experimental Arm, participants will receive selumetinib via oral capsule. In the Placebo Comparator Arm, participants will receive placebo via oral capsule.